Abstract. In the past thirty years, nerve growth factor (NGF) has received much attention for its potential role as a therapeutic agent for Alzheimer's disease (AD) due to its neurotrophic activities on basal forebrain cholinergic neurons. This attention has been renewed by recent findings that provide new causal links between defects in NGF signaling, transport or processing to the activation of the amyloidogenic route and, more generally, to AD neurodegeneration. Thus, the concept of therapeutic administration of human recombinant NGF in AD patients has a strong rationale, being further validated by recent and ongoing clinical trials with a gene-therapy approach. However, the widespread clinical application of gene or cell-therapy strategies for the delivery of NGF to AD patients seems unpractical, and it would be more advantageous to have non-invasive methods, that should also limit the adverse effects of NGF in activating nociceptive responses. This review will describe: 1) the data from preclinical and clinical studies underlying the rationale of NGF as a potential therapeutic agent for AD; and 2) the alternative strategies to reach adequate concentrations of NGF in relevant brain areas while preventing the onset of adverse effects.
INTRODUCTION
Progressive and inexorable synaptic and neuronal loss occurs in Alzheimer's disease (AD), leading to cognitive decline. Synapse loss is the major correlate of cognitive impairment in AD, in comparison to the classical neuropathological hallmarks of AD (amyloid plaques and neurofibrillary tangles) [231] . The discovery of the selective vulnerability and disruption of the cholinergic system in AD [73, 247] laid the ground for the "cholinergic hypothesis" of AD [19, 96] and for associating the cholinergic hypofunction with cognitive deficits typical of AD [96, 213] . It has been postulated for a long time [12] that deficiencies in neurotrophic factors in targets of innervation cause neuronselective neurodegeneration. Neurotrophic factors, as a class, therefore offer the potential to treat neurodegenerative disorders, by preventing neuronal degeneration and by compensating for cell and synapse loss after (or while) it has occurred. Neurotrophic factors of the neurotrophin family offer the additional potential benefit that they influence not only the survival of target neurons, but also their synaptic functions [112, 130] .
Nerve growth factor (NGF) [148, 149] , the first member of the neurotrophin family, supports neuronal survival during development and influences neuronal function throughout adulthood. In the central nervous system (CNS), mature basal forebrain cholinergic neurons (BFCNLs) are highly dependent on the availability of NGF for the maintenance of their biochemical and morphological phenotype and for survival after lesions or CNS insults [89, 108, 110] . For these reasons, exploitation of NGF activities on BFCNs may provide an attractive therapeutic option for preventing cholinergic cell death and improving the function of cholinergic neurons by preserving their synapses. However, the development of an NGF therapy is constrained by the dual conflicting need to achieve adequate concentrations in the relevant brain areas containing degenerating target neurons while preventing unwanted adverse effects on non-target regions or cells. In this article, we will describe: 1) recent preclinical cell and animal studies that broadens and further strengthens the rationale and the scope for the NGF therapeutic approach; 2) the present difficulties and obstacles facing the targeted delivery of NGF to the CNS in relation to the adverse effects to be avoided; and 3) the alternative strategies to reach adequate concentrations in relevant brain areas while preventing the onset of adverse effects. We shall then describe the two main approaches currently pursued to meet the NGF therapeutic window, in order to develop a successful therapy based on NGF, namely the genetherapy approach and the nasal delivery of recombinant forms of NGF.
Finally, the neurotrophic option can, in principle, be pursued with other neurotrophins [e.g., brainderived neurotrophic factor (BDNF)] or with small molecule approaches that target the NGF signaling and metabolism cascade at different levels, and a brief critical overview will be provided.
RATIONALE FOR THE DEVELOPMENT OF AN NGF-BASED THERAPY FOR AD

NGF and AD: The cholinergic connection
In the CNS, BFCNs provide major projections to the cerebral cortex and the hippocampus and cortical cholinergic mechanisms are directly involved in superior cognitive functions such as learning and memory [96] . BFCNs have been identified as the most significant NGF-sensitive target population. BFCNs express both TrkA and p75
NTR NGF receptors [110, 117] , are able to retrogradely transport NGF from their cortical projections up to their cell bodies [113] , and respond to administration of exogenous NGF with an increase of cholinergic phenotypic markers [98, 163] . This connection has provided a first strong argument to link NGF and AD [118, 190] .
Although NGF availability does not appear necessarily an absolute requirement for the survival of BFCNs in development, at least as concluded by gene knock-out studies [72, 82] , an extensive body of compelling evidence establishes that NGF prevents neuronal death or age-related atrophy in BFCNs from the adult brain [139] . NGF is able to prevent BFCN death, following axotomy [89, 109, 137] and to ameliorate the morphological and behavioral effects of their agingdependent atrophy [89] . Most importantly, the relevance of NGF-mediated neurotrophic and neuroprotective actions for potential human applications was further strengthened by studies on adult nonhuman primate brains. In rhesus macaque and cynomolgous monkeys, NGF prevents degeneration of BFCNs after lesions and reverses spontaneous, age-related cholinergic neuronal atrophy [236, 237] .
Thus, NGF prevents the death and stimulates the synaptic cholinergic function following a wide range of different neuronal damage mechanisms in rodents and non-human primates.
Interestingly, a reduced expression of the TrkA receptor has been demonstrated in BFCNs and neocortex from AD brains [57, 168, 169] , and loss of TrkAexpressing BFCNs has been described in mild cognitive impairment (MCI) [170] and in early AD neuropathological stages [170] . The decrease of TrkA expression appears to parallel cognitive decline [68] . Remarkably, the AD-linked decline in TrkA cortical contents does not occur for the p75 NTR receptor, determining disequilibrium in the TrkA/p75NTR ratio that might have functional consequences. Therefore, the putative "off Trk" cycle of deficient NGF signaling may contribute to the selective degeneration of cholinergic neurons observed in AD [69] .
NGF and AD: The retrograde transport connection
NGF is retrogradely transported from the cortical and hippocampal targets, where it is synthesized, to BFCN cell bodies [113, 136] . Studies on NGF mR-NA and protein expression in AD patients provided no evidence that failed synthesis of NGF in target areas causes degeneration of BFCNs [99, 127, 215] . On the contrary, increased levels of NGF and proNGF proteins in the target cerebral cortex and hippocampus of AD postmortem brains were found, together with decreased NGF immunoreactivity in the basal forebrain [83, 84, 167, 215] , suggesting a defect in the NGF retrograde transport system in AD.
This led to the prediction that, more generally, failed axonal transport of NGF signals might provide a common link between reduction of NGF trophic support, cholinergic dysfunction and neurodegeneration [211] .
Cytoskeletal transport dysfunctions are, indeed, a common hallmark of AD [128] . Neurofibrillary tangles, and tau pathology in general, could physically block transport of the NGF signaling complex. Indeed, defective transport might result from increased expres-sion [227] or hyperphosphorylation of tau and the ensuing microtubule destabilization [6, 7] . Alternatively, it might result from abnormal glycogen synthase kinase 3β (GSK3β) phosphorylation of kinesin or other transport proteins [164] .
Evidence of a role for amyloid-β protein precursor (AβPP) in axonal transport provides another significant element to the NGF, AD and retrograde transport connection. AβPP was shown to function as a membrane receptor for kinesin-1, mediating the axonal transport of cargo proteins such as BACE, PS-1, GAP43, synapsin, the "Sunday-driver" SYD and TrkA [101, 106, 128, 129] .
Increased AβPP expression in trisomy 16 mutant mice has also been directly linked to reduced retrograde transport, with particular regard to defective transport of NGF, resulting in cholinergic neuronal degeneration [64] which can be reversed by exogenous, direct NGF delivery to BFCN cell bodies [64] .
On the other hand, NGF deficits could directly contribute to axonal transport defects, through a modulation of tau expression, tau hyperphosphorylation or tau proteolysis. Thus, in PC12 cells NGF induces tau expression [80] , thereby contributing to the observed effect of NGF to promote microtubule assembly in these cells [26] . On the other hand, deprivation of NGF in cells [175] and in mice [40, 47] induces a strong and specific hyperphosphorylation of tau. Moreover, in aged anti-NGF mice, tau appears to be abnormally cleaved at N-terminally located caspase cleavage site, concomitantly with a significant upregulation of caspase activity [65] . N-terminal cleavage of tau appears to be also found in AD brains, as tangles become extracellular [33, 119] . The functional consequences of the anti-NGF induced loss of the N-terminal 25 aminoacids of tau correlates well, also, with the recent report of Frontotemporal Dementia with Parkinsonism-17 (FTDP-17) mutations of an Arginine residue in the N-terminus of tau, that dramatically affects tau interaction with dynactin [154] . Thus loss of the N-terminal portion of tau would results in a tau protein that is unable to interact with the dynactin complex and having an impaired ability to support axonal transport functions.
These findings suggest that a deregulation of intracellular transport and of axonal transport mechanisms, by different causes linked to AβPP, tau, and NGF signaling and/or processing abnormalities, might be one crucial aspect for initiating a negative neurodegeneration loop in AD (see tau loop in Fig. 5 ), leading to a further reduced neurotrophic support to BFCNs. This also suggests that therapeutic NGF replacement adjacent to cholinergic cell bodies, rather than in axon terminal regions, would bypass transport defects and allow NGF signaling at the soma [62, 135] .
The emerging complexity of NGF signaling and processing: proNGF/NGF unbalance and AD Other mechanisms, besides intracellular neuronal transport defects, could account for a reduced neurotrophic support to BFCNs, inducing their loss, or atrophy, in AD neurodegeneration. An unbalance in the proNGF/NGF ratio is another possibility of increasing relevance.
NGF, like the other neurotrophins, is translated as a pre-pro-protein [222] . Two splicing variants lead, respectively, to the formation of a long and a short form of precursor protein. Both proteins are glycosylated in vivo, yielding different molecular weight forms identified [84, 86, 147, 165, 173, 181, 201] (Fig. 1A) .
The signal peptide mediating secretion is cleaved upon translocation into the endoplasmic reticulum. In the trans-Golgi network, the pro-peptide is further processed by furin at a very conserved dibasic amino acid site, resulting in the release of the 26 kDa mature neurotrophin [86, 165, 166, 173, 216] . Other proteases, besides furin, can cleave the pro-peptide in the extracellular space [37, 147] , in particular plasmin and matrix metalloprotease-7 (MMP-7).
Biological activity of NGF precursor protein
The pro-domain was originally proposed to assist in proper folding and secretion of neurotrophins [228] and to act, in vitro, as an intramolecular chaperone of recombinant human NGF expressed in E. coli [131] . Conversely, the mature NGF region is strictly required for proNGF to be correctly folded and structurally organized [131] . An intramolecular interaction of the NGF pro-peptide region with the mature part was reported [103, 132] . The first available structural data, suggest that the proNGF domain, which has the property of an intrinsically unfolded domain, can exist in at least two conformations, an extended one, and a more compact one, in which the pro-domain folds back on the well structured mature NGF part of the protein [182] .
Recently it was found that in cultured neurons, proNGF exhibits a higher affinity for p75
NTR than for TrkA and can induce p75
NTR -dependent apoptosis [102, 147, 184] . ProNGF can also bind to TrkA and induce neuronal survival, although to a lesser extent than mature NGF [87] . Upregulation of Fig. 1 . A -Schematic representation of the major translation products arising from alternative splicing of the NGF transcript: the long pre-proNGF form of 34 kDa (a) and the short pre-proNGF form of 27 kDa (b). The two forms differ by the additional pro-sequence stretch I of 66 amino acids at the N-term of the long form A. Upon removal of the signal sequence, the two products give rise to two proNGF proteins: the long form of proNGF of 32 kDa and the short form of proNGF of 25 kDa. The arrows mark the cleavage sites for furin, the double headed arrows represent the C-terminal processing site (post translational modification) and hexagons the potential N-glycosylation sites. B -Proposed scheme for the signaling of NGF and proNGF, involving Sortilin receptor, besides the "traditional" receptors p75 NTR and TrkA. The p75 NTR /sortilin and p75 NTR /TrkA receptor pairs can be expressed either on different cells (top left and top right "cells") or on the same cell (bottom center). In the latter case, the outcome of proNGF signaling will likely depend on the relative ratios of NGF/proNGF ligands, as well as of their relative signaling through the p75 NTR /sortilin and p75 NTR /TrkA receptor pairs. Figure modified from Nykjaer and colleagues [176] .
proNGF was found to be causally linked to p75 NTRmediated oligodendrocyte (expressing p75 NTR , not expressing TrkA) death following spinal cord injury [20] .
ProNGF was also found to be a physiological ligand for p75
NTR in corticospinal neurons after axotomy and to induce neurons death through p75
NTR [102] . More-over, microglia-derived proNGF has been shown to promote photoreceptor cell death via p75 NTR [226] . In humans, ProNGF can also be detected in extracellular fluids such as cerebrospinal fluid (CSF) after lesion [17, 102] . ProNGF was also found to be the predominant form of NGF in normal brain and its levels increase in the brain of patients affected by AD [84] .
These findings opened a new scenario, whereby the balance between cell death and cell survival might be determined by the ratio of proNGF and mature NGF secreted by cells (reviewed in [50, 55, 111] ). The discovery of sortilin, a member of the Vps10p-domain receptor family, as a specific receptor for proNGF [176] , added one more variable to the emerging complexity of the NGF system.
The proNGF receptor
Sortilin is a type I transmembrane protein expressed in a wide number of developing and adult tissues. Sortilin interacts with the pro-region of proNGF with high affinity and does not bind mature NGF. ProNGF simultaneously binds Sortilin (via the pro-sequence) and p75 NTR (via the mature NGF), creating a ternary complex [156, 177, 181, 245] . The binding of Sortilin to proNGF was found to be essential for proNGF-induced neuronal cell death through p75 NTR in various cell types known to undergo apoptosis mediated by proNGF and blocking the proNGF/sortilin interaction could inhibit proNGF-mediated apoptosis [176] .
Expression of exogenous sortilin in Schwann cellsnormally expressing only p75
NTR -renders them sensitive to proNGF-induced apoptosis [176] . Moreover, proNGF promotes motor neuron death [79] , an effect inhibited by blocking proNGF binding to sortilin [79] .
Sortilin is, therefore, a third important receptor player in neurotrophin signaling. Indeed, sortilin might serve as a co-receptor and molecular switch, enabling neurons expressing TrkA or p75
NTR to respond to a pro-neurotrophin and to initiate pro-apoptotic (or "pro-neurodegeneration", see below) rather than prosurvival action (reviewed in [214] ). In the absence of sortilin, a regulated activity of extracellular proteases may cleave proNGF to mature NGF, promoting Trk-mediated survival signaling. However, there is also evidence, in BFCNs, that the sole presence of the p75 NTR and sortilin receptors is not sufficient to induce pro-neurotrophins-dependent apoptosis [245] . At the same time, the presence of both Trk and p75 NTR receptors is not enough to protect these neurons from pro-neurotrophin induced apoptosis [245] . Likewise, a recent study proved that pro-neurotrophins binding to Trk receptors required endocytosis and intracellular proteolysis, thus indicating a subtle equilibrium in pro-neurotrophins biological effect upon different levels of expression of the receptors system [34] . Preliminary findings suggest that cortical sortilin levels are increased in AD patients compared to normal controls ( [69] ). Pro-neurotrophins and their signaling through p75
NTR has been proposed to be involved in alterations of the translational machinery in AD neurons [241] . The balance between the TrkA and p75
NTR levels and distribution could be critical in determining synapse structure and the prevalence of the pro-neurotrophins through p75
NTR signaling could be linked to decreased dendritic spine complexity [241] .
Recently, a sortilin-deficient mouse was generated [125] , which allowed proof that the association between sortilin and p75
NTR is required for death signaling, and furthermore that proNGF is the pro-apoptotic factor in vivo. Furthermore, this study demonstrated that knocking out sortilin does not allow the normally occurring, age-related cell death in superior cervical ganglia (SCG), showing that the sortilin/proNGF pathway is involved in aged neurons death.
The link between pro-neurotrophins and age-related neurodegeneration was further confirmed [1, 2] , by showing that sortilin levels are elevated in aged SCG and BFCNs, together with elevated proNGF levels. A schematic representation of this complex situation is depicted in Fig. 1B .
Therefore, an updated description of neurotrophin activity in vivo involves two ligands (NGF and proNGF) and their three receptors: TrkA (predominantly for NGF), sortilin (for proNGF) and p75 NTR (for both NGF and proNGF) [50, 112, 122, 152] . In this view, the occurrence of programmed cell death mediated by pro-neurotrophins, via the p75 NTR /sortilin complex, would result from an equilibrium including the regulated processing of pro-neurotrophins as well as the spatiotemporal control of sortilin availability. This feature might explain why not all p75
NTR -positive cells undergo apoptosis in response to proNGF (reviewed in [214] ). In this view, the p75 NTR emerges as a key player [18, 177, 197, 203] .
To date, little is known about the signaling pathways elicited by the sortilin-p75 NTR complex, but several possibilities exist. Sortilin might simply function to facilitate proNGF binding to p75
NTR . Alternatively, its cytoplasmic tail might provide a template for adaptor proteins to modulate or even activate p75
NTR signaling [177] . Others proposed that sortilin, by binding to the pro-neurotrophins at the Golgi level, might protect it from proteolytic cleavage and activation [35] . Indeed, binding of pro-neurotrophins to sortilin has been proposed to be involved in the control of their sorting pathways [56, 112, 151] .
In one scenario, proNGF was suggested to act as a "baseline" neurotrophic factor with lower activity, as a reservoir for neurotrophically more active mature NGF -when survival and/or differentiation signaling is needed -or as a facilitator of death pathways -when apoptosis is required, or after injury or stress [8, 86] .
In conclusion, proNGF and pro-neurotrophins are truly independent ligands, with distinct physiological functions and, most relevant, with signaling properties [14] , widely distinct from those of mature NGF, and not merely intracellular precursors (reviewed in [112, 241] ). It should be noted that the distinction, and the discussion [86, 112] , between the pro-survival actions of NGF versus the pro-apoptotic actions of proNGF [86, 112] is an extreme, and probably artificial view. The actions of proNGF might be more adequately described as favoring, or contributing to, neurodegeneration in a broader sense (see Fig. 1B ), through signaling pathways distinct from those activated by NGF [14] .
Anti-NGF AD11 mice as an experimental model for proNGF/NGF unbalance
The distinct, pro-neurodegeneration, signaling properties of proNGF lead to postulate that an imbalance in the NGF versus proNGF availability contributes to AD neurodegeneration [43, 44, 51] . Several findings are consistent with this view. The subtle equilibrium between pro-neurotrophins and their mature forms is tightly regulated via furin-specific cleavage and/or via a cascade of extracellular proteases [37, 112, 152] . Pathological alterations of this cascade might lead to the lack of proper neuronal trophic support in pathological states, like AD, by altering the NGF/proNGF ratio.
Interestingly, proNGF isolated from human AD brain, which effectively induces neuronal apoptosis mediated by p75
NTR [184] , was found to functionally differ from that found in control brains (e.g., altered glycosylation and more efficient induction of p75 NTR processing) [192] . According to this view, in early phases of AD, signaling in cholinergic neurons would change from a pro-survival to a pro-apoptotic (or proneurodegeneration) one, as the TrkA levels decline. p75
NTR levels would remain unchanged, sortilin levels increase and proNGF levels rise in cortical projection sites during the progression of AD [2, 69] .
A significant demonstration of the functional consequences of a disequilibrium in the NGF/proNGF ratios comes from the anti-NGF AD11 mouse model [49] . AD11 anti-NGF mice represent a comprehensive murine model to study the functional consequences of an unbalance between proNGF and mature NGF and its relationship to AD neurodegeneration. AD11 anti-NGF mice express, in the adult brain, a recombinant form of a well characterized anti-NGF mAb αD11 antibody [48, 71] , in which the constant regions of the rat immunoglobulin have been substituted with the human constant regions, to allow the detection of the antibody against the mouse background [206] . AD11 mice progressively develop, from 1.5-2 months onwards, a comprehensive neurodegeneration as well as functional and behavioral impairments that encompass several features of human AD. AD11 anti-NGF mice show a progressive impairment of working memory revealed by analysis of behavioral tasks such the object recognition test [24, 40, 74] , radial maze [40, 206] and Morris water maze [24, 40, 74] . Synaptic plasticity deficits underlie the behavioral effects. Long term potentiation is decreased in the AD11 cortex [180, 187] . In the CA1 area of AD11 hippocampus, nicotine fails to enhance the synaptic efficacy of Schaffer collaterals [225] as it normally does, a deficiency linked to a rearrangement of the GABAergic hippocampal circuitry [202] .
The histological analysis reveals a neurodegenerative phenotype of classical known targets of NGF signaling, such as BFCNs ( Fig. 2A, B ) and sympathetic and sensory ganglia [39, 47, 206] . In addition, starting from two months onwards, and well correlating with the behavioral and functional deficits (Table 1) , the brain of AD11 mice is characterized by a progressive and widespread increase of neurons expressing hyperphosphorylated [40, 47] (Fig. 2C, D ) and truncated forms [65] of the microtubule associated protein tau in the cortex (starting from the enthorhinal cortex [47] ) and hippocampus and by intracellular (first) and extracellular (at later stages) accumulation of amyloid-β, located above all in the hippocampus (Fig. 2E , F and [42, 47] ).
The overall neurodegenerative phenotype of AD11 mice can be fully reverted by NGF administration [41, 74] , showing that it is indeed the result of NGF sequestration by the antibody, and firmly proving that NGF sequestration in the adult mouse brain results in ADlike neurodegeneration. But how can we explain this in mechanistic terms? The biochemical properties of anti NGF mAb αD11 [48] , which is expressed in the brain of AD11 mice, provides an answer. Table 2 Binding constants of the αD11 antibody towards rm-NGF and rmproNGF samples.
In vitro binding affinity measurements showed that mAbαD11 binds NGF and proNGF in qualitatively and quantitatively different ways ( Fig. 2G and Table 2 ). The binding of the antibody to NGF was found to be virtually irreversible, characterized by smaller dissociation constant than of proNGF (K D = 10 −12 and 10 −9 for NGF and proNGF respectively). Overall, the antibody is characterized by three orders of magnitude higher affinity for NGF than for proNGF, with a very different binding kinetics towards the two NGF forms.
The preferential binding of mAbαD11 to mature NGF, with respect to proNGF and the different binding kinetics, naturally lead the proposal of a mechanism for the onset of the anti-NGF induced neurodegeneration in the AD11 mice model. Thus, mAb αD11 would determine, under limiting concentrations in the mouse brain, an experimentally induced functional imbalance between NGF and proNGF [44, 49] , by irreversibly "sequestering" mature NGF, while leaving proNGF free to act in the functional "absence" of mature NGF. In particular, proNGF would activate the pro-neurodegeneration, pro-amyloidogenic pathways, through interaction with the sortilin and p75 NTR receptors. A first demonstration of this prediction [43, 44, 49] comes from studies in which AD11 mice have been crossed to p75
NTR homozygous knock-out mice (p75 NTR [146] ). In keeping with the prediction, the resulting offspring (AD12 mice) shows a complete reversion of the amyloid-β (Aβ) phenotype in the hippocampus [44, 49] (Fig. 3) .
Thus, a mechanistic characterization of the AD11 model allowed to show that an experimentally-induced, incorrect balance between unprocessed proNGF and NGF signaling is indeed able to determine the onset and progression of AD-like neurodegeneration in the mouse brain: the "too little NGF-too much proNGF" hypothesis for AD neurodegeneration [44, 49] (Fig. 4) .
AβPP/TAU PROCESSING AND NGF SIGNALING: LINKING NGF DEFICITS TO THE ACTIVATION OF THE AMYLOIDOGENIC NEURODEGENERATIVE CASCADE
Results from the anti-NGF AD11 mouse model demonstrate that an experimentally-induced unbalance between unprocessed proNGF and NGF signaling is indeed able to activate the amyloidogenic arm of AβPP processing. In addition to the connection linking NGF transport and AβPP intracellular trafficking (see above), this provides a significant and direct demonstration of the complex interplay and cross talk be- tween the NGF ligand(s)/receptor(s) and the AβPP signaling systems [107, 204] . In turn, NGF deficits have also profound influences on the aberrant phosphorylation or proteolysis of tau (see above). On the side of the NGF system, the ligand NGF/proNGF (dis)equilibrium (see above) is paralleled by a corre- sponding (dis)equilibrium at the level of the receptors. Indeed, an aging pathway has been shown to control the TrkA to p75 NTR receptor switch and Aβ peptide generation in cells [66] .
A further link connects the modulation of AβPP phosphorylation by the NGF receptor TrkA, coupling AβPP via the Shc/Grb2 adaptor proteins to signaling pathways associated to survival [208, 229, 230] . In addition to the AβPP-TrkA interactions, the NGF and the AβPP systems show an additional cross-talk between Aβ and p75 NTR [67, 252] . On one hand, the p75
NTR undergoes regulated intramembrane proteolysis by γ-secretase, with the γ-cleavage sites of AβPP and p75
NTR being highly homologous, releasing p75
ICD to transmit a signal to the nucleus, in analogy to the ICD signal derived by the cleavage of AβPP [209] . On the other hand, Aβ peptide binds trimers as well as monomers of p75 NTR and activates receptor signaling [252] . While the impact of such a cross-talk on AD is still debated, recent work provides significant functional evidence, directly linking NGF deficits to the activation of the AD amyloidogenic pathway [157] . The withdrawal of NGF from NGF-differentiated PC12 cells induces a rapid increase in AβPP levels and an overproduction of Aβ peptide. At the same time, the cells undergo a progressive apoptotic death. These effects could be blocked by treatment with either inhibitor of β-and γ-secretases or with antibodies directed against Aβ. In addition, silencing of AβPP mR-NA with siRNA treatment also reduces Aβ production and prevents NGF removal induced cell death. This provides evidence for a mechanism in which a discontinued or limited supply of NGF can activate a pathological pathway of AβPP processing, triggering downstream apoptotic cell death [157] .
NGF can be therefore considered as an antiamyloidogenic factor, that normally keeps the amyloidogenic pathway under control. Accordingly, whenever a normal neurotrophic supply of NGF to target neurons is shortened or interrupted, the amyloidogenic pathway is activated and a negative feedback, toxic loop is activated. Further contributing to this negative loop is the one connecting NGF and tau pathology.
CONCLUSION I: THE NGF HYPOTHESIS FOR NEURODEGENERATION
A challenge in unraveling AD has been to bridge the knowledge of the molecular mechanism of rare, early onset, familial forms to the etiology of the common late-life disorder. Although the clinical and neuropathological phenotypes of the dominantly inherited forms are closely similar to those of "sporadic" AD (save for age of onset), precisely why cerebral Aβ levels are increased in the latter remains elusive [219] .
Therefore, there is great interest to take into consideration the "non-genetic elevators of Aβ" and the preceding discussion highlights the conclusion that neurotrophic deficits and/or abnormal processing of neurotrophins provide a direct link with the activation of pathological amyloidogenic pathways. From this picture, we can therefore conclude that the links between NGF and AD go well beyond the long established neurotrophic actions on BFCNs and formulate an updated version of the NGF hypothesis for AD neurodegener- On the left side of the scheme, the "normal" conditions, when the NGF signaling is achieved mainly through the NGF/TrkA/p75 NTR system; this is the condition when "survival or neurotrophic signaling" takes place. On the middle-right part of the scheme, the representation of the pathological conditions: in red, the AD conditions, in magenta the AD11 mouse model condition. In both cases, an unbalance in the proNGF/NGF takes place, with the functional consequence of a reduced available amount of circulating mature NGF. In these conditions, the favored signaling pathway is the "neurodegeneration/cell death" one, involving proNGF, p75 NTR and sortilin. Among the "other factors", we suggest an emerging role for NGF and a functional unbalance of its transport, processing and receptor interactions (see green box at the bottom of the figure), leading to the establishment of a negative loop between the neurotrophic system, the amyloid cascade and tau pathology. The green arrows in the figure mark this suggested NGF-AβPP and the NGF-Tau loops in LOAD. These loops are interconnected.
ation, whereby the common link is a failure or an insufficient NGF signaling, leading to inadequate neurotrophic support. The failure or unbalance of NGF support could be due to different causes in the overall cascade(s) of events involving NGF bioactivity: 1) decreased synthesis; 2) unbalanced or altered processing; 3) alterations in receptor expression and/or activity or expression ratios; and 4) altered retrograde transport.
These events would be "located" upstream of the "amyloid cascade", as currently described [217] , but would be part of a negative feedback loop that involves several feedback steps from the downstream process itself (e.g., links between AβPP, tau and axonal transport), also directly involving functional connections between NGF and the tau system. Also, the cellular targets for NGF actions, in this negative loop, could be more widespread than envisaged so far. A scheme of the possible events or pathways linking NGF to the Aβ cascade is depicted in Fig. 5 . Within this theoretical frame, any therapy aimed at re-establishing the correct balance between ligands (and receptors) of the NGF pathway appears to have a clear and strong rationale.
NGF-BASED THERAPIES FOR AD
NGF clinical applications: problems to be solved
Having established that re-equilibrating a correct balance between ligands (and receptors) of the NGF pathway is a therapeutically relevant target, also for its connections and links at the core of AβPP metabolism, it is clear that the therapy of first choice would be to use NGF itself as a drug. The viable clinical application of NGF requires providing a solution to major obstacles, linked to effective CNS delivery and limitation of adverse effects (most notably, pain).
NGF does not readily cross the blood brain barrier (BBB) due to its size and net charge. Ever since the discovery of the capacity of NGF to rescue BFCNs, the delivery of NGF to the CNS was an issue, and experiments in animal models resorted to NGF intracerebroventricular (ICV) infusions, to prove the ability of NGF to prevent BFCN degeneration [89, 108, 133, 236] . On the basis of these studies, the ICV way of NGF delivery was employed in the very first clinical trials in AD patients [81, 179] 
(see below).
A second issue is represented by the well-established pro-nociceptive (or algogenic) action of NGF on the sensory neurons of dorsal root ganglia and spinal cord, on which it modulates the transmission of pain signals [189] , and a pro-inflammatory action on inflammatory cells (including mastocytes [4] ), on which it activates the release of inflammation mediators [23] .
In humans, the capacity of NGF to cause pain has been demonstrated in clinical trials in AD patients (see below), as well as during clinical trials undertaken to explore the potential use of NGF in polyneuropathies [11, 188] . The subcutaneous and intravenous injections of NGF into the arms of healthy volunteers produce allodynia and hypersensitivity of the skin surrounding the point of injection. The problem with minimizing its nociceptive algogenic effects also exists for the topical and local NGF treatment, such for ocular pathologies [141] .
In conclusion, a clinical application of NGF is limited by a double constraint, of achieving an adequate and pharmacologically relevant concentration in target brain areas, while preventing its access to non-targeted areas, where adverse effects, such as pain, are elicited.
First clinical pilot trials
The two first NGF clinical trials were based on the ICV infusion of NGF directly to the brain. The first trial was performed using murine NGF infused into the right ventricle of a single patient, at a rate of 75 µg/day for 3 months. Positron emission tomography (PET) studies demonstrated modest increase in [
11 C]nicotine binding and cerebral blood flow in the frontal and temporal cortices at the end of the infusion [121, 179] . Weight loss was reported as an adverse effect in this first trial [121, 179] .
A second clinical pilot trial was attempted in three AD patients [81] using ICV infusions of mouse NGF. Two of these patients received 75 µg/day while the third was infused with 16 µg/day for 2 weeks and later at a rate of 3.4 µg/day for 10 weeks. In these patients, a transient increase in scores was observed in some episodic memory tests and there was an improvement in physiological parameters of brain function, such as nicotine binding, cortical blood flow and electroencephalographic activity [81] . No improvements were shown in the Mini-Mental Status Examination (MMSE) scores. The trial was discontinued after the onset of debilitating side effects due to NGF infusions. In particular, the patients developed back pain within 2 to 14 days after the beginning of ICV infusions and weight loss. These side effects were interpreted on the basis of animal studies, reporting that ICV infusions of NGF provoked weight loss, sympathetic axon sprouting around the cerebral vasculature, and migration and expansion of Schwann cells into the medulla oblongata and the spinal cord [89, 123, 248] . Thus, no other clinical trial using this way of administration was performed and alternative methods of delivery were explored.
Gene-therapy approach
These results highlighted the fact that a viable clinical testing of NGF has to fulfill a dual need, to be effectively delivered to the brain regions containing target neurons, while limiting excessive spread to no targeted regions, to avoid adverse effects. Gene and cell therapy methods have been considered as one approach to specifically deliver NGF to the cholinergic neurons of the basal forebrain in a spatially restricted way. In an ex vivo gene therapy approach, cells are genetically modified in vitro to express a gene of interest, and are then implanted into the brain where they effectively act as biological micropumps, secreting the desired protein.
The efficacy of the NGF gene delivery approach to the BFCNs was tested in rodents and primates, showing the effectiveness in preventing the cholinergic neuronal degeneration after lesions in the adult brain [29, 238] and to ameliorate age-related atrophy [29, 53, 223] .
These preclinical results prompted to begin an 18 month, open label, prospective Phase I clinical safety trial of ex vivo NGF delivery in humans, which involved a dose escalation design in eight AD patients [239] . The trial was designed to protect cholinergic neurons from degeneration and augment the function of remaining cholinergic neurons by directly elevating choline acetyltransferase (ChAT) function in neurons. Patients were screened for the diagnosis of probable AD of mild severity. Autologous fibroblasts, obtained from three skin biopsies on each patient, were cultured, and genetically modified to produce and secrete the human NGF protein. The patients underwent neurosurgery, for the intracerebral injection of their own primary fibroblasts into the region of BFCNs in the brain, where neurons underwent atrophy as a result of AD. Of the eight tested patients, two subjects experienced sub-cortical hemorrhages during the stereotaxic cell injection, with consequences such as hemiparesis, and in one case, death due to cardiac arrest. The patient that survived was not included in the outcome of the trial. The trial resulted a nearly 40-50% reduction in their rate of decline on the MMSE and Alzheimer's Disease Assessment Scale-Cog (ADAS-Cog) scales [239] . In the time period from 6 months to 18 months after the implant of NGF secreting cells, two of six patients showed an actual improvement in mental function, one showed no decline in function, two worsened only mildly, and one continued to show a typical AD rate of worsening [239] . During the 6-18 month time period, a "high" NGF production is expected to be present and sufficient time has passed to allow NGF to "remodel" and stimulate the cholinergic neurons. Patients also showed a significant improvement in PET scans, after undergoing NGF treatment. The subject who underwent autopsy showed a significant cell growth effect due to the exposure of cholinergic neurons to NGF [239] . The outcome of this first trial prompted a second Phase I clinical trial, based on a direct, in vivo, NGF gene delivery into the brain, via an Adeno Associate Virus (AAV)-vector system (CERE-110). Results in animals indicate that NGF transgene delivery is reliable and accurate, that NGF transgene distribution can be controlled by altering the dose, and that it is possible to achieve restricted NGF expression limited to, but covering, the target brain region [27] . NGF transgene expression appears to be stable and sustained at all time points, with no loss or build-up of protein over the long-term [27] . In addition, results indicate that CERE-110 is neuroprotective and neurorestorative to BFCNs in the rat fimbria-fornix lesion and aged rat models, and has bioactive effects on young rat BFCNs [27] . Based on these preclinical findings, a Phase I clinical study to evaluate the safety and efficacy of CERE-110 in AD subjects, is currently ongoing [58] .
In addition to the AAV-NGF/CERE-110 trial, a new, cell-based in vivo delivery system has been developed and a Phase I trial is currently ongoing [174] . This biodelivery platform is based on the demonstration that immortalized, allogenic fibroblasts, engineered to secrete NGF and encapsulated within a polymer membrane, effectively prevented the loss of cholinergic neurons after fimbrial transections in rats [115, 116, 135] . The biodelivery technology consists of a catheter-like device that contains genetically modified cells enclosed behind a semi-permeable membrane that permits the influx of nutrients and outflow of the therapeutic factor(s) but does not allow direct contact of the foreign cells and the host brain [135] .
A non-invasive approach to NGF therapy in AD: NGF as drug for AD
The NGF gene/cell therapy approaches provide an important validation of the therapeutic potential of NGF in AD, and the outcome of the clinical studies will provide important insights into the safety, efficacy and liabilities of NGF therapies. However, the approach is impractical to be extended to the large number of people suffering from AD, since the ex vivo or in vivo administration modality is invasive and rather dangerous and expensive (requiring hospitalization) [240] and does not appear to be suitable as prophylactic cheap Fig. 6 . Proposed definition of a therapeutic window in the NGF delivery. The red traces refer to the CNS, the blue ones to the systemic/blood system. On the axis: concentration of the intranasally delivered NGF (abscissa), concentration of NGF that reaches the CNS (left ordinate axis, red) and the concentration of the NGF that reaches the blood (right ordinate axis, blue), respectively. The solid lines represent the increasing amount of NGF that reaches the CNS (red line) or the blood (or CSF) (blue line), respectively. The red and blue dashed lines respectively represent the CNS therapeutic threshold and the pain-inducing threshold (from blood stream or CSF). The "therapeutic window" (white region) is defined as the NGF dose region between the minimal NGF concentration to reach the CNS, and the dose that reaches the pain-inducing threshold in the circulating (or CSF) NGF, after nasal delivery. The left-side, red colored region represent the NGF concentrations that are not high enough to reach the CNS. The right-side, blue colored region represents the NGF concentrations that reach higher than the pain-inducing threshold in blood stream (or CSF). treatment for millions of aging people worldwide [212] . Therefore, a route for an effective, non-invasive, delivery of recombinant forms of NGF to the brain would appear to be more practical in the medium to long term, and this approach should be pursued. Indeed, the benefits of peripheral NGF administration would include elimination of the risks and expense of cranial injection, and the ability to adjust or terminate dosing.
In principle, different approaches for the development of NGF as a drug, could be pursued, a systemic delivery or a more targeted delivery (such as intranasal delivery).
The success of an NGF-based therapy by the intranasal delivery route will require meeting an NGF therapeutic window, to optimize the access to CNS, while minimizing the systemic NGF levels, to avoid unwanted pain effects (Fig. 6) . The two critical parameters in the NGF therapeutic window are the threshold concentration of NGF (in the bloodstream or in the CSF) inducing pain and the NGF levels in the target brain areas required to be pharmacologically effective. Any NGF administration route must be verified against these two parameters. For instance, for a systemic endovenous delivery of NGF (in humans), the threshold concentration of NGF that determines pain and mialgia is a dosage of 1 µg/kg [188] , while the threshold dose of NGF needed to achieve a measurable concentration in the brain in humans is estimated to be ≈ 11 µg/kg (see below).
NGF systemic delivery
A systemic administration route for an NGF-based therapy for AD is limited by the transport across the BBB. Indeed, the permeability of radioiodinated NGF at the brain nerve barrier was found to be significantly low [194] , with a permeability coefficient x surface area 16.1 fold higher than albumin [193, 194] , a marker of vascular permeability.
Thus, attempts have been made to modify NGF so as to improve its ability to cross the BBB. Antibodies against the transferrin receptors located on the BBB endothelial cells, as well as drugs conjugated to them, can cross the BBB [92, 183] . NGF was conjugated to the OX-26 antibody to the rat transferrin receptor and was shown to retain biological activity [93] . Upon systemic administration, NGF-OX26 was shown to improve spatial learning ability and to increase the size of cholinergic neurons in the medial septum in lesioned and aged rats [16, 52, 134] . The conjugation to the OX-26 antibody determined a 4.5% increase in the percentage of NGF detectable in the brain parenchyma [93] . However, OX-26 does not bind to the human transferrin receptor, making impossible to translate this technology to the clinic. Moreover, chemical crosslinking of two proteins, such as NGF and an antibody, is not easily translatable into a pharmaceutical product.
To further exploit transferrin, or its receptor, as carriers for targeting and delivery of NGF to the brain, two recombinant NGF fusion proteins were engineered by joining the human NGF precursor to the heavy chain variable region of a chimeric antibody, specific for the human transferrin receptor [160] , or by linking transferrin to the carboxyl terminus of NGF, via the hinge region from human IgG3 as a flexible linker [10] . Both proteins bind human transferrin receptor and NGF receptors and retain full NGF activity in PC12 cells [10, 160] but they were never tested in vivo.
A second approach takes advantage of the fact that covalent modification of NGF with natural polyamines, such as putrescine, determines a 10-fold increase in the permeability coefficient at the BBB, compared to the one of native NGF, but also a 6-fold decrease of the half-life of plasma NGF [195] . Such covalent modifications of the NGF, either by glycation or polyamine modification, facilitate its permeability at the BBB to physiological doses that are capable of eliciting a bioresponse [196] .
Recently, a new approach was undertaken, through the encapsulation of NGF into liposomes (NGF-SSL-T) in which RMP-7, a ligand to the B2 receptor on brain microvascular endothelial cells, was incorporated into the liposomes' surface. The delivery of NGF through the intravenous route determined a 2-fold increase in permeability of NGF to the BBB, with the majority of NGF distributed in striatum, hippocampus and cortex [251] .
In conclusion, NGF can indeed be engineered or modified in order to increase its permeability across the BBB and the concentration that reaches the CNS upon systemic administration. However, the improvements in BBB permeability obtained are not enough to achieve the therapeutic concentration in the brain, while remaining below the pain inducing threshold and to offset the complications of having an entirely new molecule with respect to NGF itself. No pain measurements, performed in the models in which transport to the brain was determined, are available to permit a comparison with NGF doses inducing pain in humans.
Intranasal NGF delivery
To date, two alternative approaches have been undertaken, in order to target NGF to the brain, while minimizing or reducing its systemic biodistribution: intranasal delivery and topical application of an NGF solution on the ocular surface. The approach to deliver drugs to the brain through the intranasal route, to circumvent the BBB, is well validated for many drugs.
In the case of AD, Phase I pilot studies based on the intranasal administration of insulin have been already conducted, in MCI and early AD patients, showing an amelioration of cognitive impairment [198, 200] , verbal memory and modulation of plasma Aβ content [199, 200] . Another substance under clinical evaluation after intranasal delivery is the activity-dependent neuroprotective protein (ADNP), which completed a Phase I study, assessing the tolerability and pharmacokinetics of intranasal administration of ADNP in sequential ascending doses in healthy volunteers [100] .
Intranasal administration of NGF through the olfactory pathway may provide a novel, non invasive, safe and effective route for the delivery of NGF to the brain, at pharmacologically relevant concentrations [41, 54, 74] , without triggering adverse side-effects.
In particular, the intranasal administration of rhNGF (recombinant human NGF) to AD11 anti-NGF mice demonstrated that the neurotrophin reaches the brain in concentrations sufficient to improve the cognitive deficit [74] and to completely rescue the neurodegeneration [41] . In AD11 mice, the intranasal route was also compared to another non-invasive route of NGF delivery to the brain, the ocular application of NGF drops. This route was previously shown to improve cholinergic markers in normal rats [142] and in mice treated with ibotenic acid [78] , but the mechanism(s) through which NGF reaches the brain after ocular delivery are not characterized [142] and, most relevant, this route was not tested in an animal model displaying a comprehensive neurodegeneration more similar to AD hallmarks. The side-by-side comparison between ocular and intranasal delivery of NGF in AD11 mice showed that the latter was much more effective in rescuing neurodegeneration, showing more specificity and less probability to induce peripheral side effects [46] . The intranasal delivery route, while leading to effective transport of NGF in AD relevant brain areas, does not lead to significant build up of NGF concentration into regions where it is known to induce pain responses in man, such as the CSF (reaching a concentration much lower than 45 pM [54] ) and in the blood stream (where it determines only a limited, albeit measurable, leakage [91] ). Thus, the intranasal delivery route appears to be an effective compromise to meet the required therapeutic window, leading to effective biodistribution in target brain areas, while minimizing the biodistribution to non-targeted districts where it is known to determine unwanted side effects.
Indeed, when administered intranasally to AD11 anti-NGF mice, NGF or its derivatives do not provide trophic support to SCG nor do they induce nociceptionrelated surrogate markers, such as calcitonin-gene related peptide (CGRP) expression in spinal cord nerve fibers, further proving that it does not reach pharmacologically relevant concentrations in the bloodstream and in the CSF [46] .
The dose of NGF administered to AD11 mice through the intranasal route (480 ng/kg), required to achieve a therapeutic effect in the brain, is 23 times lower with respect to the dose that should be administered via endovenous injection (≈ 11 µg/kg) to achieve the same NGF concentration in the brain. If these dosage were applicable to a human treatment, the intravenous dose (11 µg/kg) is ten times higher than the dose that was shown to trigger a nociceptive response in man [188] .
Thus, the intranasal delivery route provides a significant advancement towards meeting the NGF therapeutic window required for a successful NGF-based therapy (Fig. 6 ). An ideal NGF product for intranasal delivery will require a careful determination of the therapeutic dose to be delivered and a favorable profile in terms of the therapeutic range (facilitated access to CNS and/or reduced nociceptive properties, with equivalent neurotrophic properties). Indeed, the concentration of endogenous NGF in the blood and tissues varies greatly among individuals, depending on individually varying conditions, such as binding to plasma proteins [91] , stress [5, 25] or hormonal balance [25, 224] . To address the problem of NGF traceability, for its accurate dosing against the background of endogenous NGF, we developed an NGF point mutant (hNGF-61) [70] aimed at conservatively tagging hNGF, making it distinguishable from endogenous NGF. A phylogenetic and structural study led to the identification of amino acid in position 61, as the tagged residue, leading to the synthesis and expression of mutein hNGF-61, in which residue Pro61 of human NGF was substituted by Ser61, present in mouse NGF. Mutein hNGF-61 shows an identical biochemical and biological activity profile and potency as hNGF, in keeping with the fact that position 61 is located in loop III of the NGF molecule (Fig. 7A) , and does not interact with both NGF receptors (Fig. 7B) , and with the fact that mouse NGF is the gold standard for NGF bioactivity. A monoclonal antibody is able to selectively distinguish hNGF-61 from the endogenous hNGF [70] . In vivo, the intranasal administration of hNGF-61 rescues the behavioral deficit, as well as neurodegeneration, in adult [46] and aged AD11 anti-NGF mice [70] . Currently under development, hNGF-61 is the first lead of a series of NGF muteins further optimized for their therapeutic use in AD, including a series of muteins displaying a reduced pronociceptive response in animal pain models [45] .
A summary of the CNS delivery methods for NGF is reported in Table 3 .
ALTERNATIVE APPROACHES
Small molecules with NGF agonist activity
In the attempt to overcome some of the drawbacks that have limited the use of NGF in therapy (pharmacokinetics, delivery, BBB transport, adverse effects), the development of small molecule neurotrophin receptor mimetics, or of NGF agonists in general, retaining the biological activity of the natural protein, was undertaken [150, 155] . The approaches towards the use of small molecules in the NGF-based therapies comprise various types of compounds, most of them based on the search for an NGF mimetic able to induce an activation of the receptors, TrkA and/or p75 NTR . Various approaches aiming to isolate small molecule mimetics are based on structural studies, starting from the tertiary structure of NGF. In particular, the identification of the structural determinants of the interaction between NGF and its receptors, allows designing mimetic peptides based on these interacting structures. This approach was pursued both to isolate p75 NTR and TrkA activating NGF mimetics (reviewed in [150] ).
The approach based on ligands targeting the p75 NTR receptor also has the potential to modulate pathophysiological mechanisms underlying AD via a number of mechanisms, including Aβ toxicity (reviewed in [150] ). The recent findings of the increasing role of proNGF in neurodegeneration of the nervous system through p75
NTR receptor (see previous paragraphs) raise the possibility of targeting the p75 NTR with small molecules, able to inhibit proNGF-induced cell death (reviewed in [150] ). One strategy is based on synthetic peptide mimetics of NGF loop I, able to interact with neurotrophins' receptors signaling and prevent cell death (reviewed in [150] ). Indeed, a recent report has shown that small, nonpeptide p75
NTR ligands induce survival signaling and inhibit proNGFinduced death [156] . These ligands, mimetic of the neurotrophin loop 1 domain, seem to activate not TrkA but p75
NTR and the downstream pathways involving NFκB and PI3K. However, high doses are required to inhibit proNGF binding. The same kind of mimetics have also been found to modulate p75 NTR -dependent motor neuron death [185] .
A different type of NGF mimetics was developed based on the Loop 4 on NGF, known to interact with the TrkA receptor [250] . Dimeric peptidomimetics based on this structural scaffold (namely P92) were shown to act as partial NGF agonists, by ERK and AKT activation and promotion of signaling activation [250] .
In a different experimental approach, another set of small molecules as NGF mimetics were developed (reviewed in [186] ), identified on the basis of three different criteria, namely structural, binding and functional mimicry. Based on these criteria, the mimetics can be identified and optimized, also through identification of target regions of the protein to mimic, namely "hot spots" (reviewed in [186] ).
Following the approach of the hot spots identification, a set of peptidomimetics was identified. Firstly, C-(92-96), a bioactive cyclic peptide mimic, resembling the C-D β-loop of NGF, was identified as a TrkAinteracting region [21, 22, 75] . This peptidomimetic was shown to act solely as a cyclic monomer and was able to induce cellular differentiation and provide trophic effects to embryonic dorsal root ganglion (DRG) cells in culture [22] . A second mimetic was identified from the analysis of the anti-TrkA monoclonal antibody 5C3, a full agonist of TrkA, by binding to its D5 domain (reviewed in [186] ). A small molecule mimetic of 5C3 was identified and termed D3, a macrocyclic ring with the peptide side chain from the complementary determining region of the 5C3 antibody. The D3 mimetic can activate TrkA and is a partial TrkA agonist, in its ability to induce cell survival and differentiation in DRG neurons (reviewed in [186] ). In aged rats, the D3 mimetic is neuroprotective and is able to improve memory and the cholinergic phenotype ( [36] ; reviewed in [186] ). A new NGF-mimetic peptide was recently identified, based on the analysis of NGF/TrkA binding regions [60] . The authors combined the NGF regions interacting with TrkA receptor, loop 1 and loop 4, in the same molecule. This resulting peptide, termed L1L4, showed a good NGF-like activity in vitro by inducing TrkA phosphorylation and differentiation of PC12 cells and DRG [60] . However, this peptide was reported to reduce neuropathic pain in the Chronic Constriction Injury animal model [60] , a finding which is inconsistent with the known actions of NGF in this model and in neuropathic pain [30, 207, 232] .
A recent report identified gambogic amide as a selective agonist for TrkA [124] . Gambogic amide was found to selectively bind TrkA, trigger its tyrosine phosphorylation, elicit PI3-kinase/Akt and MAPK activation, provoke neurite outgrowth in PC12 cells and prevent neuronal cell death [124] .
A different class of small molecules with NGF agonistic activity relies on the finding [144] that the TrkA receptors can also be activated in the absence of neurotrophins, through transactivation by G-protein coupled receptor ligands. The first agonist molecule shown to activate TrkA in PC12 cells was shown to be adenosine, a neuromodulator that acts through G proteincoupled receptors. This finding raised the possibility to approach the treatment of neurodegenerative diseases by using adenosine-base small molecules in order to target population of neurons that express both adenosine and Trk receptors [144] . Adenosine administration showed a dose-dependent nociceptive effect that should be taken into consideration in clinical applications [104] .
In the same line, was the finding that pituitary adenylate cyclase-activating polypeptide (PACAP) is also able to activate TrkA by transactivation. PACAP is a neuropeptide, acting through G protein-coupled receptors, and was shown to activate the Trk receptors and induce survival response in hippocampal cells [145] . The Trk activation required a long time course. Regarding the application of PACAP as a TrkA receptor activator, the possible side effects of the induction of neuropathic pain should be taken into account, although results on nociceptive effects of PACAP in animal models are still controversial [9] .
The findings that adenosine and PACAP are able to activate TrkA receptors raises the possibility that the transactivation of Trk receptors by G protein-coupled receptors might be a general mechanism involved in cell survival and synaptic plasticity [145] , exploitable for therapeutic purposes in AD and neurodegeneration.
Along the same lines is the recent finding that zinc ions mediate transactivation of the BDNF receptor TrkB, thereby potentiating hippocampal synaptic plasticity [120] (see below). Also, glucocorticoids, including dexamethasone, have been recently shown to selectively activate Trk receptors in neural cells [126] , by a mechanism that does not appear to involve G-proteincoupled receptors (GPCR), but rather a genomic action of glucocorticoids. Glucocorticoids are known to induce the synthesis of neurotrophins (see below), but the activation of Trk receptors by glucocorticoids was shown not to depend on increased production of neurotrophins [126] .
In conclusion, small molecule ligands with NGF agonist activity might lead to the development of neuroprotective compounds for the treatment of neurodegeneration, but this will require a new and full understanding of their properties in vivo, with respect to the wealth of information that is available for NGF protein itself. Moreover, some of the small molecule compounds have often a mixed agonistic and antagonistic profile, making it difficult to predict their behavior in vivo.
NGF synthesis inducers, NGF processing modulators, proNGF antagonists, other neurotrophins
Other strategies to increase the NGF neurotrophic support to the brain could, in principle, be pursued, intervening with low molecular weight compounds at different points of the NGF metabolism cascade. These include NGF synthesis inducers, proNGF/NGF processing modulators, proNGF antagonists and other neurotrophins.
NGF synthesis inducers
The synthesis of NGF could be induced in the brain by several classes of compounds, each of which will, of course, have different activity profiles on other targets, which needs to be considered for their pharmaceutical development. In this review, we will report only data supported by in vivo experiments.
Among drugs acting on neurotransmitter receptors, synthesis, uptake or release, clenbuterol, a β2 adrenoreceptor agonist, selectively induces the biosynthesis of NGF in rat cerebral cortex but not in the hippocampus [90] , while the α2-adrenoreceptor antagonist dexefaroxan induces a 2-fold increase in NGF protein levels in both the cortex and nucleus basalis of Meynert (NBM) in cortical devascularized rats [76] . Selegiline, a MAO inhibitor, induces NGF gene expression in cerebral cortex from intact rats and protected rat and mouse cortical tissue from ischemic insult after occlusion of the medial cerebral arthery [220] . Single, physiologically-active and non-convulsive doses of the three GABA(B) receptor antagonists CGP 36742, CGP 56433A and CGP 56999A increase NGF mR-NA levels by 200-400% and protein levels by 200-250% in rat neocortex, hippocampus as well as spinal cord [105] . The corticosteroid dexamethasone induces a 100% NGF mRNA and protein expression versus control in neonatal and young rats, but only a modest increase was found in aged rats [59] , but in other systems it was found to inhibit NGF expression [15] . The neuropeptide cholecystokinin-8, which promotes a variety of neurobehavioral effects both in man and rodents, induces an increase in both NGF protein and mRNA in mouse cortex and hippocampus when intraperitoneally injected at physiological doses and protects central cholinergic neurons against fimbria-fornix lesion [233] . Among hormones, thyroxine increases the concentration of NGF mRNA in the septum and hippocampus in rats after an early postnatal treatment [153] .
Interestingly, some drugs that are/were under clinical evaluation for AD can induce NGF synthesis. The xanthine derivative propentofylline, an inhibitor of adenosine uptake, was shown to increase NGF synthesis and release in cultured mouse astrocytes [221] and to recover cholinergic neuronal dysfunction induced by the infusion of anti-NGF antibody into the rat septum after oral administration [95] . The acetylcholinesterase inhibitor Huperzine A, currently in Phase II clinical trial, increases NGF mRNA and protein levels after transient cerebral ischemia [246] . Finally, xaliproden, an orally-active non-peptide compound, has been found to exhibit NGF effects in vitro and in vivo, to increase the lifespan and delay the progression of the motor neuron degeneration in a mouse model of progressive motor neuronopathy [13] .
While in principle it could be advantageous to have low molecular weight compounds, ideally orally bioavailable, to increase neurotrophin concentrations (selectively) in the brain, the state of existing compounds of this nature is still rather immature. The task of identifying activators of NGF transcription or expression will require the development of adequate screening methods, such as yeast artificial chromosome based systems [15] , but the selectivity of the compounds and their pleiotropic effects will require case by case ad hoc in vivo characterization.
NGF processing modulators
As explained in the previous sections, proNGF is likely to be involved in cell death and neurodegeneration and to be a key player in AD. Moreover, the levels of proNGF in the brain were found to be increased in the brains of AD patients [84] . For this reason, in the design for new therapeutic approaches to the disease, one possible target would be proNGF itself. It is still unknown whether the increased levels of proNGF in the disease states are due to an increase in the NGF synthesis or to a decrease in the protease activity of the proteases normally involved in its processing. Therefore, in designing new potential compounds for the disease, one possible approach would be to increase the degree of processing of accumulating proNGF, by the identification of NGF processing modulators.
There are several classes of proteases known to cleave proNGF, both intracellularly and extracellularly. In particular, the pro-protein convertases are the most important class of proteases, being involved in the normal processing of proNGF to mature NGF. Among others, the ones identified were furin, PACE4, PC5/6-B [216] .
More recently a whole set of extracellular proteases were also involved in the cleavage of proNGF [147] : these are plasmin, MMP-7, MMP-3. Plasmin was also involved into the protease cascade of proNGF upon activity-dependent release, together with MMP-9 [37] .
The possibility to modulate the activity of these proteases by selective activators would be a chance to act on the proNGF levels in disease states. However, given the wide distribution of the proteases and their targets, the modulation of their activity would be totally nonselective and therefore a putative therapeutic intervention should be designed in order to tightly regulate their activity or to target specific cell populations, affected in the disease.
proNGF antagonists: Neurotensin
Another possible target, in the framework of the investigation towards the use of the neurotrophin system in the therapeutic intervention for AD, would be to consider possible proNGF antagonists, able to compete for its binding to the specific receptor, sortilin. The natural ligand for sortilin is the neuropeptide neurotensin, known to interact with three receptors: the first two neurotensin receptors (NTR1 and NTR2) belong to the family of G-protein-coupled receptors (GPCRs), the third one is sortilin [244] . Neurotensin has been reported to be involved in cellular functions in the peripheral immune system [244] , through the interaction with the NTR1. However, the effects mediated by the binding of neurotensin to sortilin are presently not fully understood [159] .
The potential use of neurotensin as an antagonist for proNGF resides on the findings that the peptide competes with proNGF for the binding to sortilin [176] . Moreover, neurotensin was shown to rescue aged SCG and basal forebrain neuron from the cell-killing effects of proNGF in vitro [2] . Consistently, alterations in the expression pattern on neurotensin and its receptors in brains of aged rats were reported [205] , and it was suggested that pharmacological manipulation of the neurotensin system could improve cholinergic neurotransmission in the brain and thus modulate and/or restore deficits in cognitive function [205] . A therapeutic approach that inactivates sortilin on the cell surface or alters its expression pattern was also suggested [172] .
It is clear that the therapeutic use of neurotensinbased compounds as an antagonist of proNGF actions in neurodegeneration will depend both on further validation of the proNGF/sortilin target in neurodegeneration and, on the other hand, on the development of neurotensin analogs devoid of the unwanted actions of neurotensin itself.
Other neurotrophins: BDNF
Other neurotrophic factors, most notably the neurotrophin BDNF and its specific receptor TrkB, are also implicated in the AD process within the context of the NGF system. BDNF is well known to be a regulator of synaptic function and synaptic plasticity [130] as well as of cholinergic neurons of the basal forebrain [212] and therefore its possible implication in AD is well grounded, also in light of AD being considered as a neuroplasticity disorder [161, 218] . Interestingly, the anatomical progression of neurofibrillary pathology in AD is well correlated to the neuroanatomy of BDNF retrograde pathways, starting from the enthorhinal to subiculum and CA1 pathway.
As NGF, BDNF exists both in pro and mature forms. The expression of both forms has been evaluated in murine models of the disease and in AD patients. In mice expressing mutated forms of human AβPP and of PS-1 (Tg2576/PS-1 P264L/+ and TG2576/PS-1 P264L/P264L mice), BDNF gene expression is upregulated following Aβ deposition [97] . At histological level, a three-fold induction of BDNF was found in microglial cells and astrocytes surrounding Aβ plaques in the APP23 mice [38] , suggesting a possible role in the regulation of inflammatory and axonal growth process around the plaque. Finally, in these mice, the improvement of cognitive functions obtained after exposure to environmental enriched conditions was shown to correlate with the upregulation of several factors including BDNF, despite a stable Aβ plaque load [249] .
The presence of BDNF polymorphisms in AD patients has been an issue of a long debate. An association of Val66Met polymorphism to AD was found by some authors [72, 88, 138, 242] , suggesting that BD-NF gene variants are significant risk factors for AD, whereas others failed to confirm it [31, 61, 77, 235, 243] .
Despite the conclusive evidence for genetic polymorphisms, alterations in both BDNF and TrkB expression were found in AD patients. The mature form of BDNF has been found to be elevated in blood serum of early stages of probable AD with respect to age-matched non demented controls and more severe stages of AD [143] . No alterations were reported in BDNF CSF levels of AD patients [28, 143] .
A 40% reduction of pro-BDNF was observed in the parietal cortex of AD patients [162] . In AD hippocampus, temporal and parietal cortex, both BDNF mRNA and protein are also decreased [63, 114, 191] . Interestingly, neurons containing neurofibrillary tangles do not express BDNF, whereas neurons with no tangles express it, suggesting a possible protective role against neurofibrillary degeneration [171] . A detailed analysis of BDNF mRNA transcripts showed that transcripts 1 to 3 are those showing a marked decrease in the parietal cortex of AD patients [85] . BDNF is also synthesized in the basal forebrain and a 50% reduction of BDNF mRNA levels was found in the nucleus basalis of Meynert [85] .
The alterations in the expression of TrkB receptor seem to be isoform specific. Indeed, a reduction of the catalytic form, but not of the non-catalytic form, has been shown in the frontal and temporal cortex of AD patients [3] . Moreover, a reduction of the number of NBM TrkB-positive neurons was found in the brain of AD patients [210] , with a greatest decrement in mild to moderate AD [97] and no changes of TrkB mRNA expression in severe AD [32] .
Overall, these data suggest that the delivery of exogenous BDNF could in principle represent a possible therapeutic approach for AD. However, the administration of BDNF is hindered by a series of problems (besides the delivery issue [91] , for which the discussion above, on NGF delivery, may apply similarly). First of all, the relationship between Aβ and BDNF and TrkB expression and activities, or of deficits thereof, are far from being described and/or clarified. Indeed, while the exposure of SHSY5Y neuroblastoma cells to Aβ 1−42 determine an increase in BDNF and TrkB expression [178] , other reports show that exposure to sublethal concentrations of the same peptide or to oligomeric amyloid decreases BDNF mRNA [94] and function [234] .
Secondly, TrkB expression in the brain is much more widespread than that of the NGF receptor TrkA, and a generalized flooding BDNF in the brain might be undesiderable, and likely to cause increased neuronal excitability and seizure development [140] . One approach, worthwhile investigating, could be to resort to activators of BDNF expression, such as antidepressants, some of which (as Fluoxetine) have been shown recently to restore cortical plasticity, via activation of BDNF expression and reduction of GABAergic inhibition [158] .
FINAL CONCLUSIONS
NGF has received much attention as a potential therapeutic agent for AD, due to its action(s) on the cholinergic system of the basal forebrain. However, the initial hopes were dampened by the fact that a practical way of delivering NGF to the brain in a safe, well tolerated and non-invasive manner has remained a considerable challenge. The NGF-based clinical approaches, currently ongoing, are still following invasive neurosurgical paradigms that, while providing further validation of the therapeutic rationale, are unlikely to become a suitable and cheap treatment for millions of patients. The attention for NGF based therapies has gained a renewed momentum by recent work that provides further significant mechanistic elements to the role of NGF in AD neurodegeneration, and place NGF at the center of a loop [the NGF/proNGF/AβPP loop (see Fig. 5 )] that could play an important etiological role in the onset and progression of the late onset, sporadic forms of the disease. It appears that different causes can lead to an altered NGF signaling, and in most of these cases (proNGF/NGF unbalance, reduced NGF availability, axonal transport deficits, etc.) enhancing the delivery of NGF may help to alleviate such causes. Therefore, the new rationale for an NGF based therapy would prospect NGF not only as a long-lasting neurotrophic cholinergic therapy, but also as an anti-amyloidogenic therapy or as a therapy that would bypass transport deficits, by providing NGF directly to the cell bodies. On the other hand, altered receptor ratios might be best approached by targeting them with receptor-specific agents.
On this basis, new approaches aimed at increasing the (effectiveness of) NGF neurotrophic support to target brain areas have a strong mechanistic basis and the development of non-invasive drugs or treatments is highly needed. The development of the hNGF-61 pipeline, optimized to meet the NGF therapeutic window by non-invasive deliveries, has the potential to yield a new generation, non-invasive, NGF-based disease modifying therapy.
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